Pfizer Phase III Lyrica study fails to meet primary efficacy endpoint
The change in endpoint mean pain score relative to baseline is the primary efficacy endpoint in the A0081242 study. In the double-blind, randomized withdrawal efficacy and safety study,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.